Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 727-732

  Hot, Arnaud ^a   Miossec, Pierre ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 17F; MESSENGER RNA; METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CARTILAGE INJURY; CELL MIGRATION; CHRONICITY; ENZYME RELEASE; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; TH17 CELL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-17; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TH17 CELLS;

EID: 79953310900     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.143768     Document Type: Review

References (72)

1. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004;36:372-8. (Pubitemid 37542434)
2. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-31. (Pubitemid 43672925)
3. Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
4. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9. (Pubitemid 38198849)
5. Chabaud M, Lubberts E, Joosten L, et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77. (Pubitemid 32303433)
6. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis:a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
7. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
8. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine 2009;46:7-11.
9. Gaffen SL, Kramer JM, Yu JJ, et al. The IL-17 cytokine family. Vitam Horm 2006;74:255-82.
10. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007;19:284-8. (Pubitemid 46597468)
11. Page G, Sattler A, Kersten S, et al. Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 2004;164:409-17. (Pubitemid 38364657)
12. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade:a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
13. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
14. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-61. (Pubitemid 47240944)
15. Rouvier E, Luciani MF, Mattéi MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150:5445-56. (Pubitemid 23180658)
16. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46. (Pubitemid 46785128)
17. Lee WW, Kang SW, Choi J, et al. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010;115:530-40.
18. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-2.
19. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9:641-9. (Pubitemid 351714729)
20. Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010;184:3336-40.
21. Lubberts E. IL-17/Th17 targeting:on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
22. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005;7:29-37.
23. Waldburger JM, Firestein GS. Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther 2009;11:206.
24. Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167:1004-13. (Pubitemid 32660858)
25. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010;32:43-53.
26. Honorati MC, Meliconi R, Pulsatelli L, et al. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford) 2001;40:522-7.
27. Zrioual S, Ecochard R, Tournadre A, et al. Genome-wide comparison between IL-17A-and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009;182:3112-20.
28. Lee J, Ho WH, Maruoka M, et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001;276:1660-4. (Pubitemid 32096603)
29. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179:7128-36.
30. Li H, Chen J, Huang A, et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000;97:773-8. (Pubitemid 30070385)
31. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603. (Pubitemid 26193037)
32. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52. (Pubitemid 46697925)
33. Starnes T, Robertson MJ, Sledge G, et al. Cutting edge:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167:4137-40. (Pubitemid 32954284)
34. Liang SC, Long AJ, Bennett F, et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007;179:7791-9.
35. Gaffen SL. Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 2004;6:240-7. (Pubitemid 39490012)
36. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
37. Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177:36-9. (Pubitemid 43939112)
38. Yao Z, Spriggs MK, Derry JM, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997;9:794-800. (Pubitemid 27494143)
39. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008;41:92-104.
40. Zrioual S, Toh ML, Tournadre A, et al. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008;180:655-63.
41. Hot A, Zrioual S, Toh ML, et al. IL-17A-versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011;70:341-8.
42. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006;281:35603-7. (Pubitemid 46041290)
43. Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007;8:247-56. (Pubitemid 46745374)
44. Awane M, Andres PG, Li DJ, et al. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999;162:5337-44. (Pubitemid 29307140)
45. Maitra A, Shen F, Hanel W, et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci USA 2007;104:7506-11. (Pubitemid 47185936)
46. Granet C, Maslinski W, Miossec P. Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther 2004;6:R190-8.
47. Patel DN, King CA, Bailey SR, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007;282:27229-38. (Pubitemid 47501976)
48. Hartupee J, Liu C, Novotny M, et al. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J Immunol 2009;182:1660-6.
49. Kehlen A, Thiele K, Riemann D, et al. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 2002;127:539-46. (Pubitemid 34437828)
50. Huang F, Kao CY, Wachi S, et al. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 2007;179:6504-13.
51. Kehlen A, Pachnio A, Thiele K, et al. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res Ther 2003;5:R186-92.
52. Chabaud M, Fossiez F, Taupin JL, et al. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14. (Pubitemid 28285549)
53. Hartupee J, Liu C, Novotny M, et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007;179:4135-41.
54. Miossec P. Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Res Ther 2008;10 (Suppl 1):S2.
55. Kim KW, Cho ML, Kim HR, et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 2007;56:1076-86.
56. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-20. (Pubitemid 33062800)
57. Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803-12. (Pubitemid 350179551)
58. Ryu S, Lee JH, Kim SI. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006;25:16-20.
59. Pickens SR, Volin MV, Mandelin AM 2nd, et al. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010;184:3233-41.
60. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001;44:1293-303. (Pubitemid 32537527)
61. Lubberts E, Joosten LA, Chabaud M, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710. (Pubitemid 30421751)
62. Van Bezooijen RL, Papapoulos SE, Löwik CW. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? Bone 2001;28:378-86. (Pubitemid 32385409)
63. Zhang Q, Wu J, Cao Q, et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 2009;60:3602-12.
64. Toh ML, Gonzales G, Koenders MI, et al. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS ONE 2010;5:e13416.
65. Moran EM, Jennifer M, Connolly M, et al. IL-17A upregulates angiogenesis, cytoskeletal rearrangement and cell migration in a chemokine dependent manner [abstract]. Arthritis Rheum 2009;60( Suppl 10):1157.
66. Tran CN, Davis MJ, Tesmer LA, et al. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis Rheum 2007;56:1497-506. (Pubitemid 46764078)
67. Gizinski A, Endres J, Lundy SK, et al. IL-17 induces production of human cartilage glycoprotein-39 in human fibroblast like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2009;60:1654.
68. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53.
69. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
70. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 (Suppl 1):i21-7.
71. Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009;206:299-311.
72. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53.